Focal Therapy in Localized Prostate Cancer: Progress and Novel Modalities

At the Society of Urologic Oncology Annual Meeting, Arvin George, MD, Johns Hopkins Medicine, and Christopher Wallis, MD, PhD, FRCSC, University of Toronto, discuss a new trial using a treatment modality for prostate tissue ablation in intermediate-risk prostate cancer.

They also hit on counseling patients on the notion of focal therapy as well as considerations for post-treatment surveillance.

Should focal therapy still be considered experimental, standard of care, or somewhere in the middle? Dr. George provides his thoughts.